Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMohamad Sheikh NajeebPGPatricia T. GreippMLMark R. Litzow

Discussion

Loading...

Member takes

Overview

Observational analysis assessed survival outcomes in patients with IDH mutations, indicating IDH2 R140 may improve response rates.

Key Points

  • Patients with IDH2 R140 exhibited superior blast cytoreduction compared to IDH2 R172, impacting outcomes.
  • Statistical analysis of 381 AML patients utilized next generation sequencing and survival analysis to assess response dynamics.
  • The study reviewed patient outcomes across different IDH mutations and their correlation with treatment responses.
  • Findings suggest IDH mutation subtypes may influence patient outcomes, indicating further research is necessary.

Cite This Study

Najeeb et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d555https://doi.org/10.1182/blood-2025-7045
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IDH2 R172 mutation is associated with improved survival in IDH-mutated AML/MDS patients undergoing allogeneic stem cell transplantation: A geth-TC multicenter study2025
  2. 2IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies2025
  3. 3Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia2025
  4. 4Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium2025
  5. 5Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia2025